News
About Cali Biosciences
加立生物科技有限公司是一家致力于创新药物研发的国际化生物制药公司,拥有制剂研发授权技术平台,以及国际化的科研与管理人才队伍。我们专注于研发应用于外科围手术期的相关药物,产品管线包括麻醉、镇痛、消炎与抗感染等领域的新药。未来我们也将推进产品的商业化,以充分回应尚未被满足的市场需求。 公司专注于创新药研发,在广东省深圳市和美国圣地亚哥均设有实验室和办公场所,同时在上海也设立了临床中心。 公司主营业务为创新药的研发与生产、注册申报,以及中美市场调研、战略运营与商业化。产品管线为以美国FDA的505(b)2为申报途径的改良剂型新药。在研发过程中和完成临床试验后,我们寻求中国、美国和欧盟监管机构的批准,旨在将创新药物推向全球市场。我们正在打造围手术期药物管线(麻醉、镇痛、消炎、抗感染),以满足全球未满足的需求。目前拥有数个临床项目资产,产品管线的目标市场巨大,临床需求明确,均为具有高技术专利门槛的复杂注射制剂。 我们的目标是服务全球病患与医护人员,并以提高人类生存与生命质量为我们的使命。
More
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.